Apurva Bansal, MD
Pulmonary Disease · Montgomery, ALNPI 1962884429
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (58.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 69.9% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $11,332, more than ten times the $23 reported in 2020.
Across 235 payments — averaging $61.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$396
- AstraZeneca$369
- Boehringer Ingelheim$296
- Grifols USA, LLC$270
- plus $1K from 21 others
What the payments were for
- Travel & lodging$1,3159%
- Food & beverage$4,65132%
- Education$8,53459%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 29 | $10,138 |
| GSK | 76 | $1,670 |
| Regeneron Healthcare Solutions, Inc. | 15 | $396 |
| AstraZeneca(2 entities) | 22 | $369 |
| Boehringer Ingelheim | 13 | $296 |
| Grifols USA, LLC | 12 | $270 |
| Mylan Specialty L.p. | 15 | $263 |
| Insmed, Inc. | 11 | $262 |
| Jazz Pharmaceuticals Inc. | 5 | $110 |
| Viatris Specialty LLC | 4 | $96 |
| Gilead | 4 | $89 |
| Sanofi | 4 | $88 |
| Amgen | 3 | $74 |
| Electromed, Inc. | 5 | $52 |
| Verona Pharma, Inc. | 2 | $39 |
| Inogen, Inc. | 2 | $39 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| United Therapeutics Corporation | 2 | $35 |
| Fisher & Paykel Healthcare Inc | 1 | $26 |
| Ambu Inc. | 1 | $25 |
| AbbVie | 1 | $24 |
| Merck | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,581
- AREXVY$361
- TRELEGY ELLIPTA$119
How this compares
$14,500 in reported general payments places this provider in the 85th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 494 | $454,055 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $250,286 |
| Dupixent PenDupilumab | 29 | $147,032 |
| TezspireTezepelumab-Ekko | 18 | $81,992 |
| Fasenra PenBenralizumab | 11 | $70,917 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 105 | $70,145 |
| Spiriva RespimatTiotropium Bromide | 57 | $37,235 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $30,559 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $21,608 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $20,572 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $16,761 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $8,431 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 238 | $7,094 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $5,901 |
| DuleraMometasone/Formoterol | 12 | $4,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,670 | $545,808640 claims |
| Grifols USA, LLCProlastin C | $270 | $250,28623 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $369 | $110,99573 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $296 | $67,795100 claims |
| MerckDulera | $21 | $4,23512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Montgomery
- William SaliskiMontgomery$257K
- Walter GribbenMontgomery$13K
- Priyanka VyasMontgomery$12K
- Adrian Noriega AldaveMontgomery$11K
- Lisa WilliamsMontgomery$9K
- Emily RehbergSylacauga$166K
- Tejaswini KulkarniBirmingham$134K
- Adrian DivittorioMobile$100K
- Luther CorleyHuntsville$86K
- Peter LutzMobile$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.